A Colombian regulatory agency fined Pfizer (PFE) nearly $25,000 for breaching the maximum prices for which the company agreed to sell several medicines in the country.
In all, the drug maker was selling its medicines from 4% to 651% above the agreed-upon levels between July and December 2016, according to a decision announced last week by the Superintendency of Industry and Commerce, an anti-competitive regulator.
About the Author Reprints
